

Fractal Kinetic Behavior of Plasmin on the Surface of Fibrin Meshwork

Imre Varjú,[‡] Kiril Tenekedjiev,[§] Zsófia Keresztes,[⊥] Andrea Edit Pap,^{||} László Szabó,[†] Craig Thelwell,[○] Colin Longstaff,[○] Raymund Machovich,[‡] and Krasimir Kolev^{*,‡}

[‡]Department of Medical Biochemistry, Semmelweis University, 1094 Budapest, Hungary

[§]Department of Information Technology, Nikola Vaptsarov Naval Academy, 9026 Varna, Bulgaria


[⊥]Functional Interfaces Research Group and [†]Department of Functional and Structural Materials, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences, 1117 Budapest, Hungary

^{||}Microtechnology Department, Institute of Technical Physics and Materials Science, Research Centre for Natural Sciences, Hungarian Academy of Sciences, 1121 Budapest, Hungary

[○]Biotherapeutics Division, Haemostasis Section, National Institute for Biological Standards and Control, South Mimms, Herts, EN6 3QG, U.K.

S Supporting Information

ABSTRACT: Intravascular fibrin clots are resolved by plasmin acting at the interface of gel-phase substrate and fluid-borne enzyme. The classic Michaelis–Menten kinetic scheme cannot describe satisfactorily this heterogeneous-phase proteolysis because it assumes homogeneous well-mixed conditions. A more suitable model for these spatial constraints, known as fractal kinetics, includes a time-dependence of the Michaelis coefficient $K_m^F = K_{m0}^F(1 + t)^h$, where h is a fractal exponent of time, t . The aim of the present study was to build up and experimentally validate a mathematical model for surface-acting plasmin that can contribute to a better understanding of the factors that influence fibrinolytic rates. The kinetic model was fitted to turbidimetric data for fibrinolysis under various conditions. The model predicted $K_{m0}^F = 1.98 \mu\text{M}$ and $h = 0.25$ for fibrin composed of thin fibers and $K_{m0}^F = 5.01 \mu\text{M}$ and $h = 0.16$ for thick fibers in line with a slower macroscale lytic rate (due to a stronger clustering trend reflected in the h value) despite faster cleavage of individual thin fibers (seen as lower K_{m0}^F). ϵ -Aminocaproic acid at 1 mM or 8 U/mL carboxypeptidase-B eliminated the time-dependence of K_m^F and increased the lysis rate suggesting a role of C-terminal lysines in the progressive clustering of plasmin. This fractal kinetic concept gained structural support from imaging techniques. Atomic force microscopy revealed significant changes in plasmin distribution on a patterned fibrinogen surface in line with the time-dependent clustering of fluorescent plasminogen in confocal laser microscopy. These data from complementary approaches support a mechanism for loss of plasmin activity resulting from C-terminal lysine-dependent redistribution of enzyme molecules on the fibrin surface.



The scaffold of intravascular blood clots that are responsible for the acute tissue damage in ischemic cardio- and cerebrovascular disease is composed of a fibrin meshwork, and accordingly its dissolution is a primary strategy in the treatment of acute myocardial infarction and stroke.^{1,2} This therapeutic approach is based on the administration of a tissue-type (or other) plasminogen activator that attacks the clot from the circulating blood and binds to the surface of fibrin forming an interfacial layer in which plasminogen is converted to plasmin, a protease capable of hydrolyzing the fibrin matrix to water-soluble degradation products (FDPs) (reviewed in ref 3). Even if plasmin is generated by a fibrin-bound activator, it needs to detach in order to attack the susceptible cleavage sites in fibrin. Thus, a layer adjacent to the surface is formed, in which free plasmin is in equilibrium with the fibrin-bound enzyme engaged in catalytic action. As a result of fibrin breakdown, this lytic front moves from the surface to the core of the clot, and the rate of its migration characterizes the overall efficiency of thrombolysis.^{4,5} Recently, direct plasmin application to the surface of thrombi has been proposed as a safe and efficient

thrombolytic modality (reviewed in ref 6). Thus, independently of the plasmin source (local generation or bulk fluid phase-borne) all available enzyme-based approaches to resolve fibrin clots involve proteolytic events at the surface of a solid phase substrate. The optimization of the current thrombolytic agents and the design of new thrombolytics would greatly benefit from kinetic models that adequately treat this heterogeneous phase catalytic process. However, at present the treatment of fibrinolysis in enzymological terms lacks a model with parameters which are mechanistically related to discrete steps of plasmin action.

The existing kinetic models of fibrinolysis fall largely into three categories. In certain cases (e.g., our earlier work ref 7) the global efficiency of proteases acting on fibrin could be characterized with phenomenological kinetic parameters that allow adequate comparison of different enzymes but lack

Received: May 29, 2014

Revised: August 15, 2014


Published: September 15, 2014



mechanistic content. A different approach builds upon diffusion, binding, and catalytic data gained in separate experiments in an attempt to reconstitute the global course of interfacial proteolysis from these discrete events.^{8–10} In these models the discrete steps are mechanistically substantiated, but due to the complex nature of the examined phenomenon a high number of independently gained parameters are necessary, which inevitably leads to simplifications to account for the variability of the conditions, under which these are derived, and thus some essential mechanistic aspects can be overlooked. For example, although 80% of the fibrin fiber volume is occupied by water,^{11,12} this space is highly compartmented by the protofibrils aligned in parallel within the fibers and by the higher ordering of the fibers encompassing three-dimensional pores. However, in environments with similar fixed geometric obstacles within cells, or in the extracellular matrix, anomalous diffusion is observed.^{13,14} Thus, any model that is based on diffusion, binding, and reaction rate parameters gained in homogeneous dilute solutions is necessarily just an approximation of the real situation in fibrin, where an additional level of complexity is rendered by the variability of fibrin meshwork structure (e.g., in cell-free areas of in vivo human thrombi the fiber diameter varies in the range 100–200 nm and the pore diameter in the range 160–380 nm).¹⁵ The third type of kinetic models of interfacial proteolysis in fibrin overcomes the limitations related to the deviation from the homogeneity assumptions by introducing a microscale stochastic approach, which operates with single enzyme molecules rather than enzyme concentrations in deterministic equations.¹⁶ This approach circumvents the necessity for assumptions of conventional transport phenomena, but its theoretical predictions for the efficiency of individual enzyme molecules have received only indirect support from experiments, because currently there are no direct data that track the behavior of separate molecules in the course of fibrinolysis. The present study was undertaken in an attempt to combine the advantages of the existing kinetic models of fibrinolysis (operating with parameters based on easily accessible empirical data) and to minimize their limitations (adding mechanistic meaningfulness to these operational parameters based on nanoscale tracing of molecular events). Following the recent advances in single-molecule experimentation, significant effort is put forward at present to express the stochastic behavior of molecules in global kinetic rate equations,¹⁷ and thus our work translates this current focus of enzyme kinetics theory to the field of fibrinolysis developing a mechanistically validated tool for experimental investigation of the process.

Fractal kinetics provides a theoretically well-substantiated approach to describe chemical reactions under dimensional or topological constraints.¹⁸ According to this concept as a result of spatial restrictions in diffusion, the reactants cluster and segregate in the course of the reactions, which implies aging of the reaction system (i.e., at identical instantaneous reactant concentrations at the time of observation, the reaction in an “older” system proceeds at a lower rate than in a “younger” one because of the more advanced degree of segregation).¹⁸ This feature of fractal kinetics is reflected in the time-dependence of the instantaneous reaction rate coefficient k , which replaces the rate constant of classic kinetics ($k = k_0(1 + t)^{-h}$, where k_0 is the initial rate coefficient, t is time, and h is a system-dependent exponent). As discussed above, fibrin forms multiple structured obstacles to fluid-borne enzymes, and thus a fractal kinetic model could be potentially adequate to describe the plasmin-

catalyzed degradation of fibrin. If the catalytic process is



where E is plasmin, Fg_R is fibrin in the reactive interface, and the rate coefficients of the separate reactions are indicated by k , the spatial constraints of the fibrin network affect only the diffusing reactant (E) resulting in a time-dependent rate coefficient for the association of plasmin and fibrin $k_1^F = k_{1,0}^F/(t + 1)^h$, the superscript F refers to the fractal kinetic approach used in the model. Thus, if the steady-state assumption is valid for discrete time intervals, the classical Michaelis–Menten equation developed originally for well-mixed homogeneous reaction systems (reviewed in ref 19) can be applied in a modified form, in which the Michaelis constant $K_{m,0}^F = (k_{-1}^F + k_{\text{cat}}^F)/k_1^F$ is replaced by a time-dependent coefficient $K_m^F = K_{m,0}^F(t + 1)^h$. A similar modification of the Michaelis–Menten model has been successfully applied in a different experimental setting.²⁰ In the present study, the analytical power of the fractal kinetic treatment of fibrinolysis has been tested on various fibrin structures and for known modifiers of plasmin action in order to establish its practical benefits.

■ EXPERIMENTAL PROCEDURES

Plasmin and Thrombin. Plasmin was generated using plasminogen (isolated from human plasma activated by streptokinase (Calbiochem, LaJolla, CA, USA) at 172.5 U/mg zymogen. Plasmin concentrations were calculated by a method described elsewhere.²¹ For all experiments in this study, the commercial thrombin preparation (Serva Electrophoresis GmbH Heidelberg, Germany) was further purified by ion-exchange chromatography on sulfopropyl-Sephadex yielding preparation with specific activity of 2100 IU/mg,²² and 1 IU/mL was considered equivalent to approximately 10.7 nmol/L by active site titration.²³

Turbidimetric Fibrinolytic Assay and Initial Data Processing. Fibrin was prepared in microtiter plates from fibrinogen (human, plasminogen-depleted, Calbiochem) at concentrations (Fg_0) in the range (1.5–5.9 μM) clotted by 5 or 100 nM thrombin for 45 min at 37 °C (in a total volume of 100 μL in 10 mM Hepes buffer pH 7.4 containing 150 mM NaCl and 3 mM CaCl_2). Thereafter 60 μL of plasmin at concentrations ($E_{0,j}^0$) nominal in the range of 0.25–1 μM was added to the surface of the clots followed by 60 μL mineral oil layered over the solution to prevent evaporation. The course of clot dissolution was monitored by measuring the light absorbance (A) at 340 nm at 37 °C. For the sake of data processing, each unique pair of nominal initial plasmin $E_{0,j}^0$ and initial fibrin $\text{Fg}_{0,j}$ concentrations was considered as a separate experiment with number $j = 1, 2, \dots, J$ performed in K_j replicas (typically eight). Within each experiment a linear dependence between the quantity of residual fibrin (F) and the measured absorbance (A) was assumed, and normalization of F was performed based on the initial and final values of A as described in Supporting Information. The mean value and the standard deviation of F were calculated for each time point of each experiment, and outliers were excluded based on criteria described in Supporting Information. The heterogeneous surface at the boundary fibrin/fluid interface resulted in variability in the amount of fibrin-entrapped plasmin, which was independently estimated following withdrawal of the fluid phase-born plasmin after 15 min incubation over fibrin in the




Figure 1. Optimized model and measured progress curves of fibrin degradation by plasmin. Fibrinogen at the indicated concentrations (Fg_0) was clotted by 5 (B) or 100 nM (A and C) thrombin for 45 min, and thereafter 1 μ M plasmin was added to the surface of fibrin and the absorbance at 340 nm was continuously monitored. The amount of intact fibrin $F_n = Fg_0 V_d$ was calculated from the absorbance data and shown as mean (symbols) and SD (continuous vertical lines) from eight replicas. The kinetic parameters were optimized according to the classic Michaelis–Menten model (A) or the fractal kinetic model (B and C), and the best-fitted predicted progress curves are presented as continuous lines, whereas the model SD is indicated by vertical dashed lines. χ^2 is the quantitative indicator for the goodness-of-fit as defined in the Supporting Information. Panel D shows the time dependence of the plasmin K_m^F predicted by the fractal kinetic model for fibrin substrate prepared from fibrinogen clotted by 5 (dotted line) or 100 (solid line) nM thrombin, the structure of which is illustrated by the inset scanning electron microscope images (in both cases fibrinogen was at 5.9 μ M, scale bar = 2 μ m). Insets in panels A–C show the distribution of molecular species expected in the Michaelis–Menten and fractal kinetics model. V_d is the volume occupied by intact fibrin at monomer concentration Fg_0 . In the reactive interface layer with volume $V_R Fg_0$ is distributed between free fibrin F_{gR} and plasmin–fibrin complex EFg . The E_{10} is distributed among free plasmin E , plasmin bound to soluble fibrin degradation products $EFDP$ and EFg .

experimental setup described above and addition of 60 μ L 0.6 mM spectrozyme-PL (H-D-norleucyl-hexahydrotyrosyl-lysine-p-nitroanilide, American Diagnostica, Pfungstadt, Germany). The amount of fibrin-entrapped plasmin was reflected in the rate of hydrolysis of spectrozyme-PL measured as changes in absorbance at 405 nm (ΔA_{405}). The uncertainties in the actual initial plasmin concentration ($E_{t,0}^0$)_{actual} were accounted for by the factor $C = (E_{t,0}^0)_{actual} / (E_{t,0}^0)_{nominal}$ with probability distribution calculated from measurements of the ratio (ΔA_{405} on fibrin surface / ΔA_{405} in fibrin-free system) and implemented in the kinetic model as described in Supporting Information.

Fractal Kinetic Model of the Fibrinolytic Process and Estimation of Its Parameters. The insets of Figure 1 illustrate the notations used for the compartments and molecular species in the model of the experimental setup described above. The reaction proceeds at the interface of the two compartments with volume V_R , which is a subvolume of V_d . The V_R compartment moves down at the same rate as the rate of fibrin conversion to FDP. As a result part of the volume V_R is continuously transforming into V_u and V_R contains constant F_{gR} (because of the progressive dissolution of fibrin, F_{gR} coincides with Fg_0). In our model the plasmin-catalyzed

degradation of fibrin in V_R is described with the following

scheme $E + F_{gR} \xrightleftharpoons[k_{-1}^F]{k_{1,0}^F, h} EFg \xrightarrow{k_{cat}^F} E + FDP$, where the rate coefficients

of the separate reactions are indicated by k . The assumption for fractal kinetic behavior of plasmin under the spatial constraints of the fibrin network results in time dependence of the rate coefficient for the association of plasmin and fibrin $k_1^F = k_{1,0}^F / (t + 1)^h$, and thus the Michaelis coefficient $K_m^F = (k_{-1}^F + k_{cat}^F) / k_1^F$ will be also time-dependent $K_m^F = K_{m,0}^F (t + 1)^h$. The interaction of plasmin with fibrin degradation products is accounted for by

a rapid equilibrium $E + FDP \xrightleftharpoons[k_{-1}^{FDP}]{k_1^{FDP}} EFDP$ characterized by $K_a^{FDP} = k_1^{FDP} / k_{-1}^{FDP}$ equilibrium binding constant yielding $EFDP = K_a^{FDP} E \cdot FDP$. For derivation of the kinetic equations of the model system the steady-state assumption $d(EFg \cdot V_R) / dt \approx 0$ is used leading to $EFg = E \cdot F_{gR} / K_m^F$ and to the differential equation $dFDP_t / dt = k_{cat}^F \cdot EFg [V_R / (V_u + V_R)] - FDP_t [k_{cat}^F \cdot EFg \cdot V_R] / [Fg_0 \cdot (V_u + V_R)]$ for fibrin degradation as described in Supporting Information. This equation is solved with the initial condition $FDP_t(0) = 0$ and based on FDP_t , V_d is calculated as a function of time until V_d reaches a value approaching V_R by 0.5% (at this terminal stage residual fibrin is present only in a volume of

1.005 V_R). Thus, finally the model function for residual fibrin is calculated $F = F_{\text{model}}(t, (E_{t,0}^0)_{\text{actual}}, Fg_0, K_{m,0}^F, h, k_{cat}^F, K_a^{FDP}) = Fg_0 \cdot V_d(t)$. Because $(E_{t,0}^0)_{\text{actual}}$ is a random variable with known distribution, the resulting F_{model} is also a random variable with mean and standard deviation estimated using triple calculation of the derived F_{model} function (see Supporting Information). The parameters $K_{m,0}^F, h, k_{cat}^F, K_a^{FDP}$ were identified by a weighted least-squares minimization of the χ^2 statistic function as detailed in Supporting Information. The confidence intervals of the optimal parameters are estimated with a multiplicative Monte Carlo simulation procedure which generates 150 synthetic data sets processed in the same way as the empirical data (the details of this approach are described in Supporting Information). All programs for data processing, model simulation, and parameter estimation described above run under Matlab 2013b (The MathWorks Inc., Natick, MA).

Scanning Electron Microscopy (SEM) Imaging of Fibrin. Fibrinogen (5.9 μM in 25 mM Na-phosphate pH 7.4 buffer containing 75 mM NaCl) was clotted for 1 h at 37 °C with 5 or 100 nM thrombin in Eppendorf tubes (pretreated with 25 v/v% Triton X-100 solution for 1 h and thoroughly washed with water). Clots were fixed, dehydrated, sputter coated with gold, and examined as described in ref 15.

Cloning and Expressing PLG_S195A_CFP. Full-length cDNA for plasminogen was purchased from HGMP Resource Centre (IMAGE clone ID: 4609295). The plasminogen coding region was amplified by PCR and ligated into pFastBac 1 (Life Technologies) to create pFastBac-PLG. A derivative of pFastBac-PLG was generated by site-directed mutagenesis (Stratagene) in which codon 195 of plasminogen was converted from AGT (serine) to GCT (alanine) to create pFastBac-PLG:S195A. pFastBac-PLG:S195A was modified to express a C-terminal fusion with enhanced cyan fluorescent protein (CFP) by modifying the plasminogen “stop” codon to an *XbaI* restriction site by site-directed mutagenesis. The *XbaI* fragment of pECFP (Clontech) that includes the coding sequence for CFP was ligated into the modified *XbaI* site to create pFastBac-PLG:S195A-CFP. The Bac-to-Bac baculovirus expression system (Invitrogen) was used to express PLG:S195A-CFP in Sf9 cells in serum-free SF900II media. PLG:S195A-CFP was secreted and purified from the culture media using a heparin agarose (Sigma) column for capture and concentration, eluting with 0.75 M NaCl onto a lysine-Sepharose (Sigma) column and eluted with 0.2 M tranexamic acid (Sigma).

Confocal Microscopic Imaging of Fibrin in the Course of Lysis. Fibrin clots were prepared from 6.5 μM fibrinogen, 2% of which was Alexa Fluor 546-conjugated fibrinogen (Invitrogen Life Technologies, Budapest, Hungary), clotted with 5 nM thrombin for 30 min at room temperature in sterile, uncoated IBIDI VI 0.4 μm -slides (ibidi GmbH, Martinsried, Germany). Thereafter a mixture of 10 $\mu\text{g}/\text{mL}$ plasminogen-S:A-CFP and 0.1 μM plasmin was added to the edge of the clot, and the fluorescence (excitation wavelength 458 nm, emission wavelength 470 nm for plasminogen-S:A-CFP detection and excitation wavelength 543 nm, emission wavelength 575 nm for Alexa546-fibrinogen detection) was monitored with Confocal Laser Scanning System LSM710 (Carl Zeiss GmbH) taking sequential images of the fluid–fibrin interface at a distance of approximately 50 μm from the plate surface with identical exposures and laser intensities using a Plan-NeofluarX20/0.5 objective. All proteins were diluted in 25 mM Na-phosphate pH 7.4 buffer containing 75 mM NaCl.

Atomic Force Microscopy (AFM) Imaging of Fibrin.

Fibrin clots were prepared from 6.5 μM fibrinogen clotted with 5 nM thrombin for 30 min at room temperature on freshly cleaved mica sheets (Ted Pella Inc., CA) in a total volume of 50 μL within 1 cm diameter rings enclosed by silicon grease. Plasmin at 1 nM was added to the clots and after 20 min clots were washed with 100 mM Na-cacodylate pH 7.2 buffer and fixated in 3% glutaraldehyde for 10 min. Following three washes with distilled water the samples were dehydrated in a 20–100% dilution series of acetone and, following a 10 min treatment with hexamethyldisilazane,²⁴ air-dried for at least 30 min. AFM images were taken with Multimode AFM head (DI, CA, USA) with Nanoscope V controller (Veeco, CA, USA) in contact mode in air at room temperature using a commercially available cantilever with a force constant of 0.12 N m⁻¹ and a Si₃N₄ tip (Veeco Nanoprobe, NP model).

Preparation of Nanogold-Labeled Antibody. Labeling of antiplasmin antibody (R&D Systems, Abingdon, UK) was carried out according to published procedures.²⁵ Briefly, sulfo-N-hydroxy-succinimido 1.4 nm nanogold (Nanoprobes Inc., Yaphank, NY) reagent was dissolved in 200 μL of deionized water immediately before use to give a 30 μM solution. The antiplasmin antibody was incubated with the activated nanogold solution for 1 h at room temperature (final concentrations: 11.5 μM nanogold, 0.61 mg/mL antiplasmin antibody). Conjugated and free nanogold were separated by fast pressure liquid chromatography using a Sephacryl S-200 HR column. Conjugated nanogold was collected and stored at –20 °C until use.

Preparation of Patterned Fibrinogen Substrate Surface with Microcontact Printing and Monitoring of Plasmin Distribution with AFM. Fibrinogen was printed on mica using microcontact printing.^{25,26} A 15 mm diameter poly(dimethylsiloxane) (PDMS) (Sylgard 184, Dow Corning) rubber stamp patterned with pillar arrays of 0.7 μm diameter was prepared by replication molding of silicon micropatterns prepared using optical lithography techniques. The PDMS stamp was incubated in 1 g/L fibrinogen (in PBS: 0.01 M sodium phosphate buffer, 150 mM NaCl, pH 7.4) for 1 h; the stamp was then rinsed in PBS for 5 min, dipped in distilled water, and dried with N₂ flush. Freshly cleaved mica was used as the substrate for stamping experiments. The PDMS stamps were placed onto the mica, and adequate stamping of proteins onto the substrate was ensured. The stamp was carefully peeled off thereafter, and the substrate surface was incubated in 1 g/L bovine serum albumin (Sigma, Budapest, Hungary) in PBS for 1 h to allow coating of areas of the surface not occupied by fibrinogen. Samples were incubated in 0.01 or 1 nM plasmin in PBS. The reaction was stopped after 1 or 5 min by withdrawal of plasmin solution and dilution with PBS. Fixing was performed with 1 v/v % glutaraldehyde in PBS for 10 min. Ethanolamine was applied for 10 min to eliminate unbound glutaraldehyde. The samples were then incubated in nanogold-labeled antiplasmin antibody (diluted to 2 mg/L in PBS) for 1 h at room temperature. Each of the above-mentioned steps were followed by rinsing the sample in PBS for 5 min. Thereafter samples were examined with AFM as described above for fibrin imaging. Images were processed using NanoScope Analysis software 1.40 (Bruker, Germany) as described below.

Height Analysis of AFM Images of Patterned Fibrinogen Surface and Determination of Bearing Percentage. The average height of stamped fibrinogen layer

Table 1. Fractal Kinetic Parameters of Plasmin on Fibrin Meshwork Substrate^a

modifier ^b	plasmin (μM)	K_m^F or K_m (μM) ^c	h (–)	k_{cat}^F (min ^{–1})	K_a^{FDP} (μM ^{–1})	χ^2
none	0.25	2.13	0.25	32.31	0.44	0.24
		(1.90–2.45)	(0.24–0.26)	(32.28–32.35)	(0.37–0.58)	
	1.0	5.01	0.16	32.31	0.84	0.45
Th100	1.0	(4.96–6.03)	(0.12–0.17)	(32.11–32.32)	(0.77–1.03)	
		1.98	0.25	42.41	0.43	0.24
		(1.80–2.22)	(0.23–0.27)	(42.39–42.42)	(0.39–0.48)	
1 mM εACA	0.25	8.44	0.03	39.23	~0	0.46
		(8.09–9.23)	(0.02–0.06)	(39.07–39.33)		
		(7.45–7.69)		(39.85–39.90)	(1.42–1.89)	
CPB	0.25	2.68	~0	41.76	1.20	0.54
		(2.39–2.84)		(41.74–41.78)	(1.11–1.34)	
	1.0	3.25	~0	41.63	1.04	0.53
		(2.59–4.03)		(40.81–45.42)	(0.65–1.65)	

^aKinetic parameters are reported as best-fitted values and their 95% confidence intervals from 150 cycles of Monte Carlo simulations using a global fitting procedure to measurements illustrated in Figure 1. ^bFibrin was prepared from fibrinogen at different concentrations clotted with 5 nM thrombin (or 100 nM thrombin indicated as Th100). For evaluation of the effect of ε-aminocaproic acid (εACA) and carboxypeptidase B (CPB) CPB was mixed with fibrinogen at 8 U/ml prior clotting, whereas εACA was added together with plasmin at the surface of the clot. ^cIf a fractal kinetic model was used ($h \neq 0$), the values of K_m^F are reported for time $t = 0$.

was determined using height analysis of samples prior plasmin digestion. Bearing analysis was carried out on $1.5 \times 1.5 \mu\text{m}$ regions of plasmin-treated samples, each containing a single square of printed fibrinogen, 27–54 regions per image at 4500× magnification or 9 regions at 13000× magnification (data analysis was carried out on four independent sets of experiments). To measure the surface area occupied by fibrinogen, bearing depth was set to 3 nm (based on results from control measurements). By setting the bearing depth value to 5 nm, the area occupied by plasmin on the surface of fibrinogen was measured. The fraction of fibrinogen surface area occupied by plasmin was expressed as relative bearing percentage = (bearing area at 5 nm)/(bearing area at 3 nm) × 100.

RESULTS AND DISCUSSION

Fractal Kinetic Treatment of Progress Curves in Fibrinolysis. The turbidimetric assay (Figure 1) is a robust experimental setup able to acquire a high number of data points to monitor the fibrinolytic resolution of preformed fibrin by fluid-phase borne plasmin. The optical signal in this assay is always proportional to the amount of intact fibrin with monomer concentration Fg_0 in the volume V_d . The catalytic process occurs in the interface formed after the addition of plasmin at concentration E_{i0}^0 in volume V_u . As a result of fibrin degradation and release of small FDPs, not optically visible, V_d continuously decreases and V_u increases with consequent dilution of free plasmin in the bulk fluid phase. However, if the classic Michaelis–Menten model was applied to the reactions in volume V_R , the dilution of reactants did not account for the deceleration trend in the progress curves of lysis (Figure 1A). Data clearly showed systematic deviations of the optimized model predictions from the measured values at all stages of the process. Importantly, our numeric treatment of the model progress curves takes into account the variability in the plasmin concentration in the reactive layer through a randomizing factor based on independent measurements of plasmin activity retained at the fluid–fibrin interface, but even with this larger standard deviation (SD) allowance arising from the initial concentration uncertainties, the values predicted by the Michaelis–Menten model differed significantly from the

measured progress curve (see Supporting Information, Figure S11). Plasmin interaction with FDPs could also contribute to the declining rate of fibrinolysis because binding of plasmin to these soluble products would withdraw protease molecules from the reactive interface layer. If this factor is taken into

account in the model as a rapid equilibrium $E + FDP \xrightleftharpoons[k_{-1}^{FDP}]{k_1^{FDP}} EFDP$ characterized by $K_a^{FDP} = k_1^{FDP}/k_{-1}^{FDP}$ equilibrium binding constant, fitting was improved (Figure S11 in Supporting Information), but the systematic deviations persisted, especially in the initial stage of the progress curves. Significant improvement in the goodness-of-fit (reduction of χ^2 from 0.95 to 0.24) could be achieved with the fractal kinetic model (Figure 1B,C). The time-dependent increase of the K_m^F value of this model (Figure 1D) in conjunction with the plasmin–FDP interaction satisfactorily described the decline of the fibrinolytic rate in the complete course of the reaction.

Dependence of the Fractal Michaelis Coefficient on Enzyme Concentration. The applicability of the fractal kinetic model was explored by following fibrinolysis over a range of conditions. Varying the plasmin concentration in the physiologically relevant range between 0.25 and 1 μM, the k_{cat}^F parameter of the model was found to remain constant, whereas the initial value of the K_m^F coefficient was more than doubled (Table 1). Such a dependence of the apparent Michaelis constant on enzyme concentration in heterogeneous phase fibrinolysis is not unexpected in view of the recently developed generic rate law for surface-active enzymes.²⁷ As elegantly demonstrated in this theoretical study, if a fluid-phase enzyme acts on a surface-bound substrate, the value of the Michaelis constant appears larger at increasing enzyme concentration because the available area for absorption decreases monotonously when more enzyme is applied. Thus, our heterogeneous phase fibrinolytic assay provides empirical support for this theoretical prediction. The accompanying decrease in the fractal exponent h of our model at higher plasmin concentration (Table 1) can be attributed to a similar effect. Over time, the available absorption area poses constant limits on the ability of fibrin to promote clustering of enzyme, but at higher concentrations more uniformly dispersed enzyme molecules are available to replenish plasmin at fibrin sites




Figure 2. Effect of carboxypeptidase B (CPB) and ϵ -aminocaproic acid (ϵ ACA) on plasmin-catalyzed fibrinolysis. (A) Fibrinogen at $2.9 \mu\text{M}$ was clotted with 5 nM thrombin, and then, after 45 min , $1 \mu\text{M}$ plasmin was added to the surface of the clot and the absorbance at 340 nm was measured (mean of eight progress curves is shown). CPB was added to fibrinogen prior clotting, whereas ϵ ACA was present only in the plasmin solution. Measured (symbols) and model simulated progress curves of lysis (continuous lines) are shown for CPB-modified fibrin (B) and 1 mM ϵ ACA applied together with plasmin (C). The best fit for the lysis in B and C was achieved according to a nonfractal model including a rapid equilibrium term for the interaction of plasmin and FDPs. Vertical bars indicate the SD of the measurement (continuous lines) and the simulation (dashed lines).

liberated in the course of clustering. The phenomenological consequence is a lower h value, i.e., a weaker time-dependence of K_m^F .

Fibrin Structure As a Modifier of the Fractal Kinetic Behavior of Plasmin. Fibrin is not a simple substrate, and a variety of structures are possible depending on the polymerization conditions (Figure 1D, insets). For example, as we and others have previously shown (refs 4, 5, and studies cited therein), fibrin formed at high thrombin concentrations resulting in thin fibers is more difficult to dissolve on a macroscopic scale than fibrin formed at low thrombin composed of thick fibers, despite the faster digestion of individual thin fibers. This apparent contradiction may now be explained by the values of the parameters of our present fractal kinetic model for fibrin formed at 5 and 100 nM thrombin (Table 1), consisting of thick and thin fibers, respectively. The moderately (by 30%) higher k_{cat}^F and 2 -fold lower initial K_m^F values for the fine fibrin structure suggest more efficient proteolytic action of plasmin on this fibrin substrate. However, the overall time course of fibrinolysis was faster in the coarse fibrin at any examined fibrinogen concentration (compare Figure 1B,C). In our fractal kinetic model this controversy is accounted for by the higher value of the fractal exponent h in the thin-fiber substrate, which results in a faster rise in the K_m^F value (Figure 1D) and thus deceleration of lysis. This fractal kinetic approach may also be understood in terms of an earlier model developed to explain fibrinolysis in fibrin composed of thin and thick fibers. According to this hypothesis proposing a “crawling” action of plasmin,²⁸ the closer distance of binding sites in the cross-section of the fibrin fibers (6 nm on neighboring monomers in transverse section versus 22.5 nm in longitudinal direction along the protofibrils) results in plasmin acting preferentially in a lateral direction leading to transection of the individual fiber. Subsequently, plasmin will dissociate and may diffuse to a remote site in the same fiber or on a different fiber. Thus, plasmin cleaves single thin fibers faster where there are fewer monomers in the cross-section, but as lysis progresses, digestion becomes more dependent on the slower diffusion steps. In contrast, the larger mass within a single cross-section requires longer time for cleaving individual fibers in coarse fibrin, but because of the fewer fibers, the decelerating effect of the propagating diffusion-mediated jumps to remote fibers is less pronounced in this fibrin architecture (lower h value, Table 1; slower increase of the K_m^F , Figure 1D). Thus, the difference in h values in fine and coarse fibrin may have a

mechanistic justification, reflecting distribution and diffusion events during fibrin lysis.

Impact of Modifiers of Plasmin–Fibrin Interactions on the Fractal Kinetic Parameters. We have recently shown that the continuous action of carboxypeptidase B (CPB) in lysing fibrin accelerates plasmin-mediated fibrinolysis through removal of newly exposed C-terminal lysine residues.²⁹ A comparable effect could be observed in a heterogeneous phase fibrinolytic assay in the presence of 1 mM ϵ -aminocaproic acid (ϵ ACA), whereas ϵ ACA at concentrations above 5 mM inhibited plasmin action (Figure 2A). The inhibiting effect of ϵ ACA is in agreement with the known interference of this lysine analogue with the lysine-dependent binding of plasmin to fibrin resulting in maximal inhibition of fibrin monomer digestion at 5 mM concentration.⁷ However, neither the CPB nor the low-concentration ϵ ACA effects can be adequately treated in quantitative terms with classical enzyme kinetic models, whereas the fractal kinetic model could be successfully applied under these modified conditions too (Figure 2B,C). The time-dependent increase in the K_m^F values was completely eliminated by both modifiers (observed as a decrease in the fractal exponent h by at least an order of magnitude, Table 1), which suggests that the newly exposed C-terminal lysines in the course of lysis are primarily involved in the hypothesized progressive clustering of plasmin that can be interpreted as aging of the system as discussed in the introduction section. The elimination of this redistribution-related aging of the enzyme in the dynamically changing fibrin meshwork resulted in a faster course of fibrinolysis either in CPB-modified fibrin or in the presence of 1 mM ϵ ACA (however antagonizing higher affinity plasmin-fibrin interactions by ϵ ACA at 5 mM or higher concentration was inhibitory). It is noteworthy that in the presence of the accelerating concentration of ϵ ACA, the K_m not only lost its time dependence, but its value was higher than the initial K_m^F in the modifier-free fibrinolytic assay (Table 1). No increase in K_m was observed in the CPB-modified fibrin, which can be attributed to two opposing consequences of the CPB action. The removal of the C-terminal lysines exposed by plasmin would raise the K_m similarly to ϵ ACA, but the presence of CPB at the stage of fibrin formation resulted in thinner fibers (e.g., 8 U/mL CPB decreases the median fiber diameter in $6 \mu\text{M}$ fibrin from 144 to 109 nm),²⁹ a structure similar to the one formed by 100 nM thrombin, in which plasmin operates with lower K_m^F (Table 1). Thus, the effects of CPB on the parameters of the fractal kinetic model support the primary role of the

progressive rise of K_m^F in the relative lytic resistance of fibrin with fine structure; if this factor is eliminated by CPB, plasmin acts with a constant lower K_m , and the overall course of lysis is significantly faster (Figure 2A).

Structural Evidence for Progressive Clustering of Plasmin on a Fibrin Surface. Because the key element of the fractal kinetic model discussed above is the clustering of plasmin molecules on the substrate surface, direct morphological evidence was also sought to substantiate this mechanism of action suggested by macroscale enzymological studies. On a microscopic scale, the distribution of plasmin on the surface of fibrin was monitored using a fluorescent recombinant plasminogen variant plasminogen-S:A-CFP, which contains all fibrin-binding sites of plasmin, but cannot exert any catalytic activity with its active site serine replaced by alanine (Figure 3).




Figure 3. Microscopic clustering of plasminogen in the lytic interfacial layer of fibrin. Alexa543-labeled fibrin was prepared as described in Experimental procedures and $0.1 \mu\text{M}$ plasmin containing active site mutated plasminogen-S:A-CFP was added to its surface. Images were taken in a confocal laser scanning microscope 1 and 5 min after initiation of lysis. The plasminogen-S:A-CFP molecules formed clusters along the lysis front, connected by a continuous layer of weaker fluorescent signal at 1 min, which was interrupted at the sites indicated by arrows at 5 min. Red channel: Alexa543-labeled fibrin (excitation 543 nm, emission 575 nm). Green channel: plasminogen-S:A-CFP (excitation 458 nm, emission 470 nm). Scale bar = $50 \mu\text{m}$.

As a result of nonfluorescent plasmin action, new plasmin(ogen) binding sites become exposed in the reactive layer, and their arrangement is revealed by binding of fluorescent plasminogen-S:A. As shown in Figure 3, following a 1 min digestion of fibrin with plasmin, plasminogen clusters were formed on the surface (linked by a continuous layer of weaker plasminogen-related fluorescence), even though the fluorescent label was applied in a homogeneous solution to the surface of fibrin. At a later stage of digestion, the sites of the earlier clusters showed no detectable accumulation of plasminogen (arrows in Figure 3). However, clusters were seen at different locations, suggesting dynamic redistribution of plasmin(ogen) at the fluid–fibrin interface with increasing degree of heterogeneity. The focal nature of plasmin action was clearly demonstrated by the nanoscale traces in the AFM images of lysing fibrin (Figure 4). However, the same images also indicate that the random spatial arrangement of the fibrin fibers does not allow objective quantitation of the degree of heterogeneity of plasmin distribution on the surface of this network. To overcome this difficulty we designed a substrate surface for plasmin with structured pattern composed of fibrinogen arranged in well-defined squares (Figure 5). Because of the regular pattern of the substrate, the relative area of intact fibrinogen covered by plasmin molecules could be reliably estimated based on the ratio of cross-section area at 5 nm height (corresponding to the nanogold-labeled antiplasmin antibody-enhanced plasmin on top of fibrinogen) and the




Figure 4. Focal nanoscale traces of plasmin action in three-dimensional fibrin meshwork. Fibrin was prepared on mica sheets and AFM images were taken as described in Experimental Procedures. The continuity of the original fibrin fibers (left panel) is interrupted by transections (arrow) leading to extensive digestive foci 20 min after application of 1 nM plasmin to the clot (right panel).




Figure 5. Distribution of plasmin molecules on patterned fibrinogen substrate surface. Square ($0.7 \times 0.7 \mu\text{m}$) fibrinogen islets of 3 nm height were prepared on mica sheets using a microcontact printing technique (A, left panel), and plasmin treatment was initiated for 1 or 5 min before stopping with glutaraldehyde. Surfaces were then exposed to nanogold-labeled antiplasmin antibody, and AFM images were collected as described in Experimental Procedures. (A) Representative images of plasmin–antiplasmin complexes attached to fibrinogen digested for 1 and 5 min with 1 nM plasmin, scale bar = $1.5 \mu\text{m}$. (B and C) The percentage of intact fibrinogen surface occupied by plasmin was determined on at least 39 AFM images of fibrinogen islets from two independent series of measurements for each time point and plasmin concentration (p values refer to Kolmogorov–Smirnov test executed on the indicated pairs of samples). The digestion time was 5 min in panel B, and the plasmin concentration was 1 nM in panel C. (D) On the basis of the results in panels A–C, a scheme is proposed for the distribution of plasmin (red dots) across a cross-section of a fibrin clot in the plane of the reactive interface (V_R defined in Figure 1). Only fibrin fibers perpendicular to the interfacial plane are shown as green circles, assuming that their transection results in FDP release. In stage I (early phase lysis), plasmin is uniformly distributed on the surface of the fibers. In stage II (late-phase lysis), the transected thinner fibers are absent from the plane of the section, whereas the plasmin molecules form clusters, the sites of which can be traced back to the loci of digestion observed in the AFM images (Figure 4).

cross-section area at 3 nm (corresponding to the height of the intact fibrinogen surface) shown as relative bearing percentage in Figure 5B,C. Visual inspection of the AFM images (Figure 5A) show that at 1 min digestion, plasmin clusters were smaller in size and more uniformly dispersed over fibrinogen than at 5

min digestion, when larger clusters were preferentially localized at the edges of fibrinogen squares. Height analysis showed that this progressive clustering was not due to an absolute decrease in the fibrinogen area available for plasmin binding but to redistribution of plasmin over the intact fibrinogen surface that could be quantitatively expressed as a bearing percentage (Figure 5B,C). Decreasing relative occupancy of the intact substrate surface by plasmin is an indicator for loss of homogeneous distribution of the enzyme that occurs progressively in time (Figure 5C) and is accelerated with the increase in enzyme concentration (Figure 5B). Microcontact printing creates a patterned, heterogeneous surface for plasmin action. However, this method does not allow utilization of highly insoluble substances, e.g., fibrin. This is a limitation of the experimental system used here because fibrinogen does not form polymers, and neither does it contain all plasmin(ogen) binding sites present in fibrin.³⁰ With this limitation in mind, the dynamic clustering of plasmin on the patterned fibrinogen surface can be translated to the hypothetical situation in fibrin according to the scheme in Figure 5D. At stage I (initial) the more uniformly dispersed enzyme and the larger available area allow for a higher rate of association to fibrin reflected in lower initial values of K_m^F (Figure 1D). At stage II (late) the generated new plasmin binding sites (new C-terminal lysines) and the decreased available area (eliminated transected fibers) restrict the probability for new binding events seen as lower association rate and consequently higher K_m^F values (Figure 1D). As the lytic front moves, stage I occurs in deeper clot layers, while stage II, focused at the top of the interfacial layer, expands, resulting in an increase of K_m^F over time.

In conclusion, our study has substantiated in mechanistic terms a fractal kinetic model that describes satisfactorily the action of plasmin on a fibrin surface. In this work, earlier theoretical predictions for the behavior of surface-acting enzymes^{18,27} and qualitative evidence for spatially constrained migration of plasmin in the network of fibrin fibers²⁸ converge in a unified concept for quantitative characterization of interfacial fibrinolysis. This concept furthers our understanding of how various factors could affect in vivo fibrinolytic rates (as exemplified by the differential effects of fibrin structure on the separate parameters of the fractal kinetic model in this study). The fractal kinetic nature of the interfacial fibrinolysis adds a self-limiting factor to the action of plasmin, which is complementary to the plasma inhibitor-dependent decay of its activity in vivo. In addition to the improved quantitative interpretation of physiological fibrinolysis, this model suggests novel strategies in the ongoing research of direct fibrinolytic enzymes.⁶ For example, it predicts that the catalytic efficiency of a protease acting on the surface of fibrin would benefit from retarded clustering of the enzyme, which could be achieved with recombinant modifications of the parent plasmin molecule (optimizing the number of its fibrin-binding sites and their fibrin affinity). An alternative strategy could be the development of plasminogen activators that occupy plasmin binding sites in fibrin and consequently combine the advantage of local generation of plasmin in therapeutic thrombolysis with prevention of plasmin clustering. Thus, this model could contribute to the rational design of better thrombolytic agents and strategies to combat cardio- and cerebrovascular disease, which remains the major cause of morbidity and mortality worldwide.

■ ASSOCIATED CONTENT

■ Supporting Information

(1) Experimental setup of the turbidimetric fibrinolytic assay, measurement and initial data processing; (2) model of a single progress curve; (3) identification of optimal parameters; (4) Monte Carlo procedure for confidence intervals of the optimal parameters; (5) Comparison of the goodness-of-fit of three kinetic models for the action of plasmin on fibrin surface. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Phone: +36 1 4591500/60035. Fax: +36 1 2670031. E-mail: Krasimir.Kolev@eok.sote.hu.

Funding

This work was supported by the Hungarian Scientific Research Fund [OTKA 83023, 100753, and 112612].

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors are grateful to Péter Fürjes for the help in silicon master preparation and to Györgyi Oravecz for technical assistance.

■ ABBREVIATIONS

AFM, atomic force microscope; ϵ ACA, ϵ -aminocaproic acid; FDP, fibrin degradation products; SEM, scanning electron microscopy; PBS, phosphate buffered saline; PDMS, poly-(dimethylsiloxane)

■ REFERENCES

- (1) Armstrong, P. W., Gershlick, A. H., Goldstein, P., Wilcox, R., Danays, T., Lambert, Y., Sulimov, V., Rosell Ortiz, F., Ostojic, M., Welsh, R. C., Carvalho, A. C., Nanas, J., Arntz, H. R., Halvorsen, S., Huber, K., Grajek, S., Fresco, C., Bluhmki, E., Regelin, A., Vandenberghe, K., Bogaerts, K., Van de Werf, F., and STREAM Investigative Team (2013) Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. *N. Engl. J. Med.* 368, 1379–1387.
- (2) Adams, H. P., Jr., del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., Lyden, P. D., Morgenstern, L. B., Qureshi, A. I., Rosenwasser, R. H., Scott, P. A., and Wijdicks, E. F. (2007) Guidelines for the early management of adults with ischemic stroke. *Circulation* 115, e478–e534.
- (3) Kolev, K., Longstaff, C., and Machovich, R. (2005) Fibrinolysis at the fluid-solid interface of thrombi. *Curr. Med. Chem. Cardiovasc. Hematol. Agents* 3, 341–355.
- (4) Collet, J. P., Park, D., Lesty, C., Soria, J., Soria, C., Montalescot, G., and Weisel, J. W. (2000) Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. *Arterioscler. Thromb. Vasc. Biol.* 20, 1354–1361.
- (5) Longstaff, C., Thelwell, C., Williams, S. C., Silva, M. M., Szabó, L., and Kolev, K. (2011) The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. *Blood* 117, 661–668.
- (6) Marder, V. J. (2011) Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin. *J. Thromb. Haemost.* 9 (S1), 364–373.
- (7) Kolev, K., Tenekedjiev, K., Komorowicz, E., and Machovich, R. (1997) Functional evaluation of the structural features of proteases and their substrate in fibrin surface degradation. *J. Biol. Chem.* 272, 13666–13675.

- (8) Diamond, S. L., and Anand, S. (1993) Inner clot diffusion and permeation during fibrinolysis. *Biophys. J.* 65, 2622–2643.
- (9) Anand, S., Wu, J. H., and Diamond, S. L. (1995) Enzyme-mediated proteolysis of fibrous biopolymers: Dissolution front movement in fibrin or collagen under conditions of diffusive or convective transport. *Biotechnol. Bioeng.* 48, 89–107.
- (10) Wootton, D. M., Popel, A. S., and Alevriadou, B. R. (2002) An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator. *Biotechnol. Bioeng.* 77, 405–419.
- (11) Carr, M. E., Jr., and Hermans, J. (1978) Size and density of fibrin fibers from turbidity. *Macromolecules* 11, 46–50.
- (12) Voter, W. A., Lucaveche, C., and Erickson, H. P. (1986) Concentration of protein in fibrin fibers and fibrinogen polymers determined by refractive index matching. *Biopolymers* 25, 2375–2384.
- (13) Dix, J. A., and Verkman, A. S. (2008) Crowding effects on diffusion in solutions and cells. *Annu. Rev. Biophys.* 37, 247–263.
- (14) Verkman, A. S. (2013) Diffusion in the extracellular space in brain and tumors. *Phys. Biol.* 10, 045003.
- (15) Varjú, I., Sótónyi, P., Machovich, R., Szabó, L., Tenekedjiev, K., Silva, M. M., Longstaff, C., and Kolev, K. (2011) Hindered dissolution of fibrin formed under mechanical stress. *J. Thromb. Haemost.* 9, 979–986.
- (16) Bannish, B. E., Keener, J. P., and Fogelson, A. L. (2014) Modelling fibrinolysis: a 3D stochastic multiscale model. *Math. Med. Biol.* 31, 17–44.
- (17) Xie, X. S. (2013) Enzyme kinetics, past and present. *Science* 342, 1457–1459.
- (18) Kopelman, R. (1988) Fractal reaction kinetics. *Science* 241, 1620–1626.
- (19) Cornish-Bowden, A. (2013) The origins of enzyme kinetics. *FEBS Lett.* 587, 2725–2730.
- (20) Kosmidis, K., Karalis, V., Argyrakakis, P., and Macheras, P. (2004) Michaelis-Menten kinetics under spatially constrained conditions: application to mibefradil pharmacokinetics. *Biophys. J.* 87, 1498–1506.
- (21) Kolev, K., Léránt, I., Tenekejiev, K., and Machovich, R. (1994) Regulation of fibrinolytic activity of neutrophil leukocyte elastase, plasmin, and miniplasmin by plasma protease inhibitors. *J. Biol. Chem.* 269, 17030–17034.
- (22) Lundblad, R. L., Kingdon, H. S., and Mann, K. G. (1976) Thrombin. *Meth. Enzymol.* 45, 156–176.
- (23) Longstaff, C., Wong, M. Y., and Gaffney, P. J. (1993) An international collaborative study to investigate standardisation of hirudin potency. *Thromb. Haemost.* 69, 430–435.
- (24) Ubero-Pascal, N., Fortuño, J. M., and de Los Angeles, P. M. (2005) New application of air-drying techniques for studying Ephemeroptera and Plecoptera eggs by scanning electron microscopy. *Microsc. Res. Technol.* 68, 264–271.
- (25) Soman, P., Rice, Z., and Siedlecki, C. A. (2008) Immunological identification of fibrinogen in dual-component protein films by AFM imaging. *Micron* 39, 832–842.
- (26) Agnihotri, A., and Siedlecki, C. A. (2005) Adhesion mode atomic force microscopy study of dual component protein films. *Ultramicroscopy* 102, 257–268.
- (27) Kartal, O., and Ebenhöf, O. (2013) A generic rate law for surface-active enzymes. *FEBS Lett.* 587, 2882–2890.
- (28) Weisel, J. W., Veklich, Y., Collet, J. P., and Francis, C. W. (1999) Structural studies of fibrinolysis by electron and light microscopy. *Thromb. Haemost.* 82, 277–282.
- (29) Kovács, A., Szabó, L., Longstaff, C., Tenekedjiev, K., Machovich, R., and Kolev, K. (2014) Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin. *Thromb. Res.* 133, 80–87.
- (30) Medved, L., and Nieuwenhuizen, W. (2003) Molecular mechanisms of initiation of fibrinolysis by fibrin. *Thromb. Haemost.* 89, 409–419.